Novartis Expects Zelnorm U.S. Approval Despite EU Filing Withdrawal
Executive Summary
Novartis continues to expect U.S. approval of Zelnorm (tegaserod) despite problems with the marketing application for the irritable bowel syndrome therapy in Europe.